

Pharmacokinetics

Systemic absorption of injected

local anesthetic from the site of administration is modified by several factors, including dosage, site of injection, drug-tissue binding, the presence of vasoconstricting substances, and the physicochemical properties of the drug. Distribution: be related with tissue perfusion, liposolubility, and pH. Excretion: first-order kinetics, $t_{1/2}$ is constant.

Therapeutic uses
 Surface anaesthesia: nose, mouth, bronchial tree (usually in spray form), cornea, urinary tract. Not effective for skin.
 (2) Infiltration: direct injection into tissues to reach nerve branches and terminals. Used in minor surgery. Adrenaline often added as vasoconstrictors (not with fingers or toes, for fear of causing ischaemic tissue damage).

(3) Conduction anaesthesia (nerve-block anaesthesia): Local anaesthetics is injected close to nerve trunks (e.g. brachial plexus, intercostal or dental nerves), to produce a loss of sensation peripherally. Used for surgery, dentistry.

(4) Subarachnoidal anaesthesia (spinal anaesthesia): LA injected into the subarachnoid space, to act on spinal roots and spinal cord. Used for surgery to abdomen, pelvis or leg. Main risks are respiratory depression and hypotension.

(5) Epidural anaesthesia: LA injected into epidural space, blocking spinal roots. Used for spinal anaesthesia, also for painless childbirth.

Adverse effects
 A₁(1) Central nervous system: --- At low doses, they include sleepiness, light-headedness, visual and auditory disturbances, and restlessness. ---At higher concentration, nystagmus and muscular twitching may occur. Finally, overt tonic-clonic convulsions followed by central nervous system depression and death may occur.

(2) Respiratory and cardiovascular system: --- Respiratory failure secondary to CNS depression is a late stage of intoxication. ---Hypotension is a late effect that can occur as the result of myocardial depression, and peripheral arterial vasodilation and autonomic nerves.

(3) Allergic reactions: Include allergic dermatitis, urticaria, hypotension, tachycardia and arrhythmia.

---It is well absorbed following parenteral administration and is rapidly metabolized by pseudocholinesterase. It has short duration of action (30-45 min). ---The metabolic product of procaine hydrolysis is PABA, which inhibits the action of sulfonamides.

Therapeutic uses: ---It can be used in all kinds of anaesthesia except surface anaesthesia.

Adverse effects: CNS---restlessness, shivering, anxiety, occasionally convulsions followed by respiratory depression. CVS--- bradycardia and decreased cardiac output, vasodilation. Allergic reactions.

Lidocaine Pharmacokinetics: It is rapidly absorbed after parenteral administration and is metabolized in the liver by microsomal mixed-function oxidases.

Lidocaine Pharmacologic effects: --- -Rapid onset of anaesthesia. ---Minimal local irritation. ---A greater potency and longer duration of action than procaine. ---Moderate topical activity.

Lidocaine Therapeutic uses: It be used widely for local anesthetic, and intravenously, as an antiarrhythmic agent. Its duration of action is 1.5 h. Adverse effects: as procaine, but less tendency to cause CNS effects.

Tetracaine Pharmacokinetics: ---It is approximately 10 times more potent (more toxic) than procaine. ---Its onset of action is approximately 1-3 min, and its duration of action is between 2 and 3 h.

Tetracaine Therapeutic uses: ---A 2% solution is used topically on mucous membranes. ---Tetracaine hydrochloride is a commonly used local anesthetic for spinal anaesthesia and, in this context, usually is combined with 10% dextrose to increase the specific gravity so that the solution is heavier than cerebrospinal fluid.

Bupivacaine Pharmacokinetics: ---It is more potent and has a longer duration of action than other LA, lasting for more than 24 h in some situations, possibly as a result of increased tissue binding.

Bupivacaine Therapeutic uses: ---It can be used in infiltration anaesthesia, conduction anaesthesia, and epidural anaesthesia. Adverse

ux x uu . . . @Times New Roman . . . !2 6-
Local Anesthetics . . . "System@
@Times New Roman . . . 2 K&→Department of
Pharmacology . . . @Times New Roman . . .
2 V: Zhang . . . @Times New Roman . . . 2 VOYan . . .
New Roman . . . 2 V]mei . . . 胀謔.←+搬+ , OH
在屏幕上显示▲yaoli 締g 締g 締g Times New Roman
宋体默认设计模板Local Anesthetics IntroductionMechanism of actionMechanism of actionMechanism of action
actionPharmacokineticsTherapeutic usesTherapeutic usesTherapeutic usesTherapeutic usesAdverse
effectsAdverse effectsAdverse effects Procaine Procaine Procaine Lidocaine Lidocaine Lidocaine
Tetracaine Tetracaine Bupivacaine Bupivacaine + ▲ 已用的字体▲演示文稿设计模板▲ 幻灯片标题
Root Entry
2|SummaryInformation(D "PowerPoint Document(締
!"#\$%&'()*+,-./0123456789:;<=>?@ABC EFGHIJKLMNOPQRSTU WXYZ
[\] h

_銻鋇 d|服务部 g 鐵疣物 | - 樂+!@!|↑|←↔▲! " # \$ % & ' () * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ?
@ABC EFGHIJKLMNOPQRSTU WXYZ[\] _`abcde h
Root Entry
汝 嗽) Current User
D "PowerPoint Document(締|DocumentSummaryInformation8 V+